1 The pharmacokinetic profile and biochemical efficacy of idrapril calcium, a novel angiotensin converting enzyme (ACE) inhibitor, were evaluated in healthy volunteers after multiple dosing for 5 days at the doses of 100, 200 and 400 mg twice daily. The study was conducted as a double-blind, cross-over comparison of idrapril calcium against placebo. 2 Plasma concentrations of idrapril were determined by an indirect enzymatic method. Urinary concentrations were measured by reverse phase high performance liquid chromatography (h.p.l.c.). Plasma samples were also analysed for ACE activity. 3 The pharmacokinetics of idrapril calcium did not change significantly between day 1 and day 5. The values of Cmax and AUC were dose-related over the range of doses tested; tmax was 3-4 h and apparent elimination half-life was 1.4-1.6 h. 4 Plasma ACE activity was maximally inhibited (94-96%) at all dose levels and remained more than 80% depressed from 2 to at least 6 h after idrapril calcium. Although the maximum effect was not dose-related, the duration of inhibition showed some dose-dependency, ACE activity returning to 56, 45 and 29% of the basal value 12 h after the 100, 200 and 400 mg doses, respectively. 5 There were no clinically significant adverse events experienced by the volunteers.
Introduction
Angiotensin converting enzyme (ACE) inhibitors cium belongs to a recently discovered class of ACE have been used successfully to treat hypertension and inhibitors, namely the hydroxamic non-aminoacid congestive heart failure for many years. The ACE derivatives [1] . Idrapril calcium differs from tradiinhibitors currently marketed are dipeptide or tional ACE inhibitors in that the amide bond is aminoacid derivatives that differ mainly in the chemi- shifted [2] , and retains the pharmacological properties of known ACE inhibitors in vitro and in vivo [3] .
Idrapril is approximately as potent as captopril, but with a longer duration of action, and experimental results obtained in guinea-pigs (capsaicin-induced bronchoconstriction) suggest that it may be less liable to produce cough in patients [3] . In healthy volunteers intravenous idrapril (I to 25 mg) dose-dependently modifies circulating renin angiotensin system (active renin, angiotensin I, angiotensin II, angiotensin 1I/angiotensin I ratio, ACE) as expected by an ACE inhibitor [4] . Idrapril calcium, a stable salt of idrapril, reduces plasma ACE activity after oral administration of 100 mg and has a bioavailability of approximately 30% [4, 5] .
The pharmacokinetic profile of single oral doses (100, 200 and 400 mg) of idrapril calcium in healthy volunteers has been reported, showing that Cmax and AUC are dose related, tmax is 2 h and elimination half-lives are 2.1-2.5 h [6] .
The objective of the present study was to investigate tolerability, pharmacokinetics and biochemical efficacy of idrapril calcium after multiple oral administration to healthy male volunteers.
Methods

Subjects
Six subjects, age 29.5 ± 11.0 years (mean value + s.d.), body weight 70.6 ± 10.7 kg, were selected from a panel of healthy volunteers held at Inveresk Clinical Research (ICR), Edinburgh. All subjects had a medical history taken, satisfied a physical examination and laboratory evaluation and had a body weight within ± 15% of their ideal. Subjects were excluded if they had taken an investigational drug in the 4 months before the study or if they needed any medication within 5 days of study entry. Additionally, those subjects who had lost greater than 400 ml of blood in the 3 month period before study entry, were excluded. All subjects gave their written informed consent to participate in the study which was approved by the On all study days subjects remained recumbent for 2 h after dosing, after which time they were permitted to be ambulant.
Blood samples were taken for haematology and clinical chemistry at screening, before morning dose on day 1 and 3, and 36 h after the last dose. ECG was performed at screening, before morning dose on each treatment and 6 h after the morning dose on day 1 and 3. Vital signs (supine systolic and diastolic blood pressure and heart rate) were measured at screening, before the morning dose on each treatment day, 2, 4, 6 and 12 h after the morning dose on day 1, 3 and 5, and 12 and 36 h after the last treatment. Urinalysis was performed using Multistix (Ames) on screening and 36 h after the last dose. Blood sampling for pharmacokinetic analysis and ACE activity was performed on a number of occasions before and after dosing ( Figures 1 and 2 ). Urine collection periods were 0-12 h after the first administration and 0-12 h and 12-36 h after the last administration.
Subjects were resident during each dosing period from the evening before dosing until 36 h after the last dose. There was a minimum wash-out period of one week between different treatments.
Analytical procedures
Plasma concentrations Concentration of idrapril in plasma was determined by an enzymatic method, based on the inhibition of a standard preparation of purified ACE by extracts of plasma samples, as previously described [5] . The limit of quantitation of idrapril was 1 ng ml-'.
Urine concentrations Concentration of idrapril in urine was determined by a h.p.l.c. method with electrochemical detection, as described elsewhere [7] .
The limit of quantitation was 2.5 pg ml-1.
Plasma ACE activity ACE activity in plasma samples was assayed by measuring the amount of hippuric acid cleaved from the substrate hippurylglycylglycine by h.p.l.c. with spectrophotometric detection, as described elsewhere [5] . Table 3 , a high inter-subject (as well as intra-subject on different days) variability was observed in urinary excretion. A maximum recovery of about 8% was obtained with the 100 mg dose on day 1 and with the 400 mg dose on day 5. No idrapril was measurable in urine collected 12-36 h after the last treatment and 0-12 h data appears to be representative of overall elimination of unchanged drug in urine.
Biochemical efficacy
Plasma ACE activity in pre-dose samples ranged from 53-131 mu ml-' with some (CV < 20%) intrasubject variability. As shown in Figure 2 , treatment with placebo did not affect ACE throughout the observation period. Idrapril calcium markedly affected ACE activity after every dose and peak inhibition (94 to 96%) at 3 to 4 h after treatment was similar with all three doses. Time to recovery towards normal activity was dose-related, inhibition values of 44 ± 5, 55 ± 6 and 71 ± 3% being found 12 h after the first treatment with 100, 200 and 400 mg, respectively. Repeated dosing did not influence the effects of idrapril calcium and almost identical inhibition curves were obtained after the ninth treatment on day 5. ACE activity had returned to basal levels by 36 h after the tenth administration.
Correlation between ACE activity and plasma concentrations ACE inhibition was found to correlate with log plasma concentration of idrapril according to a sigmoidal function (Figure 3) . Idrapril concentration capable of inducing 50% inhibition of plasma ACE was virtually identical on day 1 -log idrapril concenraion (ng ml-') Following oral administration of idrapril calcium, peak concentrations were reached within 3-4 h at any dose level and Cmax and AUC were correlated to dose, while the terminal half-lives (1.4-1.6 h) were dose-independent. In previous single dose studies, terminal half-lives were 1.5 h (100 mg, [5] ), 2.1-2.5 h (100-400 mg, [6] ) and 2.9 h (100 mg, [4] ). These differences can be explained by the difficulty of correctly estimating the terminal half-life with ACE inhibitors, known to have a complex, not single-expo- t nential elimination from plasma [9] . Indeed the above half-lives were estimated over different time spans: up to 12 h from treatment in the present study and up to 12, 24 or 36 h, respectively, in the previous studies [4] [5] [6] .
Moreover, delayed absorption maxima and reduced peak concentrations and AUCs were observed in this study compared with the previous ones. A reasonable explanation for this discrepancy can be sought in the protocols of the different studies: when idrapril calcium was administered as a single dose [4] [5] [6] , subjects remained fasting for at least 4 h after treatment, whereas in the present study they received a standard meal soon after drug administration. The possibility exists that food interferes with idrapril absorption and bioavailability, as reported for captopril [ 10, 11] .
Idrapril was found to be eliminated by renal excretion, although in amounts that are below those expected after the estimated oral bioavailability of about 30% [4] . This might be related to reduced absorption of idrapril calcium in the present study, as discussed above. The possibility that an alternate metabolic route of elimination exists for this compound is currently being investigated.
Comparison of pharmacokinetic parameters on day 1 and day 5 of treatment suggests that idrapril calcium does not have time dependent pharmacokinetics. Plasma concentrations at any dose were statistically indistinguishable throughout the study and no consistent signs of accumulation or altered disposition were observed.
At all tested dose levels idrapril calcium inhibited plasma ACE to approximately the same extent (. 94%), while duration of action was dose-related. These biochemical effects were very similar on day 1 and day 5 and substantial inhibition appeared after 12 h at any dose level. Inhibition of plasma ACE and the antihypertensive effect of ACE inhibitors are not simply temporally related [9, 12] . In a recent study performed in patients with essential hypertension, a single oral dose of idrapril calcium (200 mg) effectively lowered supine and erect blood pressure up to 24 h, a time when plasma ACE had returned to normal [13] .
In conclusion, idrapril calcium appears to be welltolerated after oral administration of multiple doses up to 400 mg twice daily in healthy volunteers. Drug accumulation or tolerance does not appear to occur after repeated administration. The duration of plasma
